Moyamoya
UMLS: C0026654
Basic Information
Severity Level:
Severe
Based on 10 similar ADEs (max similarity: 0.471), includes 10 severe case(s)
Definition:
A noninflammatory, progressive occlusion of the intracranial CAROTID ARTERIES and the formation of netlike collateral arteries arising from the CIRCLE OF WILLIS. Cerebral angiogram shows the puff-of-smoke (moyamoya) collaterals at the base of the brain. It is characterized by endothelial HYPERPLASIA and FIBROSIS with thickening of arterial walls. This disease primarily affects children but can also occur in adults.
UMLS ID:
C0026654
MeSH ID:
Synonyms:
Moyamoya
Moyamoya Disease
Moyamoya Disease
Moyamoya Disease
Progressive Intracranial Arterial Occlusion
Progressive Intracranial Arterial Occlusion Syndrome
Disease (Or Disorder); Moyamoya
Disease Moya Moya
Disease Moyamoya
Moya Disease
Moya Moya Disease
Moya-Moya Disease
Classification Hierarchy
MeSH Tree Number breakdown for C0026654
C10
Nervous System Diseases
C10.228
Central Nervous System Diseases
C10.228.140
Brain Diseases
C10.228.140.300
Cerebrovascular Disorders
C10.228.140.300.200
Carotid Artery Diseases
C10.228.140.300.200.600
Moyamoya Disease
C10
Nervous System Diseases
C10.228
Central Nervous System Diseases
C10.228.140
Brain Diseases
C10.228.140.300
Cerebrovascular Disorders
C10.228.140.300.510
Intracranial Arterial Diseases
C10.228.140.300.510.200
Cerebral Arterial Diseases
C10.228.140.300.510.200.737
Moyamoya Disease
C14
Cardiovascular Diseases
C14.907
Vascular Diseases
C14.907.137
Arterial Occlusive Diseases
C14.907.137.615
Moyamoya Disease
C14
Cardiovascular Diseases
C14.907
Vascular Diseases
C14.907.253
Cerebrovascular Disorders
C14
Cardiovascular Diseases
C14.907
Vascular Diseases
C14.907.253
Cerebrovascular Disorders
ADE Molecular Mechanism Mapping
Drug-ADE-Human Protein Triplets
Molecular mechanism triplets showing drug-adverse event-protein relationships
0
Total Triplets
0
High Confidence
Loading Drug-ADE-Protein triplets...
Personalized Drug-Protein-ADE Network
Comprehensive Information for Personalized ADE
Comprehensive Information and Reliability for Drug-ADE Association
Drug Confidence Filter
DTA Confidence Level
Layout Style
Show Labels
Total Drugs
58
2 High |
11 Medium |
45 Low Confidence
Total Proteins
0
Target proteins associated with this ADE
Drug-Protein-ADE association
0
0 Known |
0 High |
0 Middle |
0 Low Confidence
Confidence Profile
0%
Known/High/Middle-confidence interactions
This interactive network visualization shows the relationships between the top 50 drugs (ranked by case number) out of 58 total drugs associated with this adverse event, their known and potential off-target proteins, and the associated adverse effect. The connections indicate binding interactions and mechanistic pathways.
Adverse Drug Event (ADE)
Drug
Protein
Drug-Center
Human Protein-Center
confidence level
Drug Confidence Level Distribution
Drug Type Distribution
Loading ADE information...
Pharmacological Target Class Distribution
Top 8 Function Target Sub Classes
Loading target information...
The Introduction of Drug-AE Confidence Score Grade
| Priority Level | Score Range | Description | Evidence Characteristics |
|---|---|---|---|
| High | Score ≥ 6.67High-priority associations requiring immediate attention. | Strong evidence across multiple dimensions with high statistical significance, robust association measures, and substantial case numbers. Warrant priority pharmacovigilance action. | High P-value scores (significant Adjust-P), Strong ROR/PRR values, Substantial case numbers, Complete dimensional coverage, Minimal data filtering needed. |
| Medium | 3.33 ≤ Score < 6.67Medium-priority associations requiring careful evaluation. | Moderate evidence quality with acceptable statistical significance and association strength. May need additional validation or monitoring before definitive action. | Moderate P-value significance, Reasonable ROR/PRR measures, Adequate case numbers, Partial dimensional coverage, Some data quality considerations. |
| Low | Score < 3.33Low-priority associations with limited evidence strength. | May represent weak signals, insufficient data, or associations requiring extensive additional investigation before any regulatory or clinical consideration. | Weak P-value significance, Low association measures, Limited case numbers, Incomplete dimensional data, Significant data filtering applied. |
The Introduction of Drug-AE Severity Score Grade
| Severity Level | Score Range | Description | Typical outcomes |
|---|---|---|---|
| Minimal | 0 ≤ Score ≤ 0.387 Low severity ADRs requiring minimal intervention. | Events that need medical attention to prevent permanent damage but without hospitalization or life-threatening consequences. | Primarily RI (Required Intervention) outcomes, Outpatient management, Preventive measures, Early intervention prevents escalation. |
| Mild | 0.387 < Score ≤ 0.861 Mild severity events requiring hospitalization. | Mix of intervention-required and hospitalization cases with manageable clinical outcomes and good recovery potential. | Mix of RI and HO outcomes, Initial or prolonged hospitalization, Active medical management, Generally favorable prognosis. |
| Moderate | 0.861 < Score ≤ 1.500 Moderate ADRs resulting in permanent disability. | Higher proportion of hospitalization and disability cases requiring intensive medical management and long-term care planning. | Increased HO and DS outcomes, Permanent disability, Extended hospitalization, Rehabilitation required, Long-term functional impairment. |
| Severe | 1.500 < Score ≤ 2.52High severity life-threatening events with significant morbidity. | Notable presence of disability and life-threatening outcomes requiring emergency intervention and intensive care management. | Prominent DS and LT outcomes, Life-threatening events, Emergency intervention required, ICU admission, High risk of permanent consequences. | Critical | 2.524 < Score ≤ 5.000Critical life-threatening or fatal ADRs with maximum clinical impact. | High proportion of life-threatening events and deaths with very strong drug-event associations requiring immediate regulatory action. | Significant LT and DE outcomes, Fatal events, Emergency life-support measures, Immediate drug discontinuation, Regulatory safety alerts. |
The Introduction of Drug-AE-Protein Confidence Score Grade
| Confidence Level | Relationships | Description | Evidence Types |
|---|---|---|---|
| Known/Valid | Direct DTA relationships | The drug-ADE, drug-target, and target-ADE associations are all derived from the same literature source. | Experimental validation, Clinical evidence |
| High | DT + TA + DA | Two of the three associations (drug-ADE, drug-target, and target-ADE) are derived from the same literature source, while the third is validated by other literature. | Multiple corroborating sources |
| Medium | DT + TA + DA | Two of the three associations (drug-ADE, drug-target, and target-ADE) are validated by separate literature sources. | Partial evidence chain |
| Low | TA + DT | Only target-ADE and drug-target associations are validated by literature sources. | Associative evidence only |
Personalized ADE
Route and Formulation-specified Associations
Pharmaceutic Granularity for Route and Formulation specification
Administration Routes (Total: 68 cases across 6 routes)
Dosage Forms (Total: 51 cases across 6 forms)
Drug Route Analysis
Drug Form Analysis
Drug Route Analysis
| Route | Drug Name | Case Number | Confidence Score | Confidence Level | Severity Score | Severity Level | Details | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading data... | |||||||||
Drug Form Analysis
| Form | Drug Name | Case Number | Confidence Score | Confidence Level | Severity Score | Severity Level | Details | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading data... | |||||||||
Disease-stratified Associations
Personalized Granularity for Disease and Indication Stratification
|
Indication Name
|
Drug Name
|
Case Number
|
Confidence Score
|
Confidence Level
|
Severity Score
|
Severity Level
|
Details |
|---|
DEV TOOL
